C. Gilbert

发表

Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial

E. Asante-Appiah, W. Rosenberg, G. Foster, 2018, Hepatology.

The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.

M. Manns, P. Marcellin, B. Bacon, 2014, Gastroenterology.

Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection.

D. Nickle, A. Howe, R. Barnard, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Immunogenicity and safety of a Haemophilus influenzae B (Hib)-hepatitis B vaccine with a modified process hepatitis B component administered with concomitant pneumococcal conjugate vaccine to infants.

S. Klopfer, T. Vesikari, F. Schödel, 2011, Vaccine.

803 RELATIONSHIP BETWEEN TRANSAMINASE LEVELS AND PLASMA PHARMACOKINETICS FOLLOWING ADMINISTRATION OF MK-5172 WITH PEGYLATED INTERFERON alfa-2b AND RIBAVIRIN (PR) TO HCV GENOTYPE (G) 1 TREATMENT-NAÏVE PATIENTS

M. Cooreman, L. Wenning, N. Mobashery, 2013 .

Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent.

M. Buti, X. Forns, A. Howe, 2015, Journal of hepatology.

Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.

M. Buti, X. Forns, A. Howe, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses

A. Lazzarin, Jinrong Zhao, R. Leavitt, 2010, Journal of acquired immune deficiency syndromes.

Safety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in renal pre-dialysis and dialysis patients.

S. Klopfer, G. Villa, J. Stek, 2009, Vaccine.

The 67th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2016.

M. Colombo, W. Rosenberg, G. Foster, 2016, Hepatology.

A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1).

F. Martinón-Torres, R. Dagan, L. Szenborn, 2023, Vaccine.

Elbasvir/Grazoprevir and Sofosbuvir for HCV Genotype 3 Infection With Compensated Cirrhosis: A Randomized Trial

E. Asante-Appiah, W. Rosenberg, G. Foster, 2018 .

Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.

A. Limaye, A. Humar, F. Vincenti, 2023, JAMA.

O001 : C-salvage: grazoprevir (GZR; MK-5172), elbasvir (EBR; MK-8742) and ribavirin (RBV) for chronic hcv-genotype 1 (GT1) infection after failure of direct-acting antiviral (DAA) therapy

M. Buti, X. Forns, A. Howe, 2015 .